TRIUMPH-Outcomes is a registered retatrutide study that asks whether assignment to the investigational compound changes serious cardiovascular events or worsening kidney function in adults at elevated risk. Its ClinicalTrials.gov number is NCT06383390. The study design addresses questions that a trial centered on average weight change cannot resolve on its own.
Who is the study designed to enroll?
The sponsor describes adults with a BMI of at least 27 and atherosclerotic cardiovascular disease, chronic kidney disease, or both. That population was selected because the trial focuses on heart and kidney outcomes. Results from this group will need to be interpreted in light of those eligibility rules.
What is a composite endpoint?
A composite endpoint groups defined events so that the analysis can measure whether participants experience any event in that group. It is useful to read the exact list in the study record. If a trial reports a difference in the combined endpoint, the size of the difference can vary across its component events.
How does this differ from a change in a risk marker?
An average change in blood pressure or cholesterol describes a measured risk marker. A clinical-outcome study can instead record whether specified events occur and how long they take to occur. The outcome definition and the length of follow-up determine what the trial can answer.
What can you conclude from the registry entry?
The registry establishes the planned comparison, population and outcomes. It does not supply a clinical result before results are posted or published. Check the record’s last update and posted results section when following the study. TRIUMPH-Outcomes is distinct from TRIUMPH-3, which has a primary focus on weight change.
Sources and further reading
TRIUMPH-Outcomes registration · Lilly’s study description · TRIUMPH-3 trial registration · FDA’s information on unapproved GLP-1 drugs
GLP Life Sciences research library · Existing TRIUMPH-1 research summary